Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients.

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14740%2F15%3A00084505" target="_blank" >RIV/00216224:14740/15:00084505 - isvavai.cz</a>

Alternative codes found

RIV/00209805:_____/15:#0000695

Result on the web

<a href="http://bmccancer.biomedcentral.com/articles/10.1186/s12885-015-1752-5" target="_blank" >http://bmccancer.biomedcentral.com/articles/10.1186/s12885-015-1752-5</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1186/s12885-015-1752-5" target="_blank" >10.1186/s12885-015-1752-5</a>

Result language

angličtina

Original language name

Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients.

Original language description

Background: The anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (moAbs) cetuximab or panitumumab are administered to colorectal cancer (CRC) patients who harbor wild-type RAS proto-oncogenes. However, a percentage of patients do not respond to this treatment. In addition to mutations in the RAS genes,mutations in other genes, such as BRAF, PI3KCA,or PTEN, could be involved in the resistance to anti-EGFR moAb therapy. Methods: In order to develop a comprehensive approach for the detection of mutations and to eventually identify other genes responsible for resistance to anti-EGFR moAbs, we investigated a panel of 21 genes by parallel sequencing on the Ion Torrent Personal Genome Machine platform. We sequenced 65 CRCs that were treatedwith cetuximab or panitumumab. Among these, 37 samples were responsive and 28 were resistant.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2015

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

BMC Cancer

ISSN

1471-2407

e-ISSN

—

Volume of the periodical

15

Issue of the periodical within the volume

October

Country of publishing house

GB - UNITED KINGDOM

Number of pages

11

Pages from-to

—

UT code for WoS article

000363502400001

EID of the result in the Scopus database

—